[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371665-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371665-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","allogeneic-cetuximab-armed-gamma-delta-t-cells-using-antibody-cell-conjugation-technology-for-the-treatment-of-egfr-expressing-solid-tumors","Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors","","Targeting the epidermal growth factor receptor (EGFR) is a strategic cancer-therapy approach, including engineered CAR-αβT modalities, yet current cell therapies face risks from genetic engineering, long manufacturing/waiting times, and high costs for autologous products. Antibody-cell conjugation (ACC) technology links cancer-targeting antibodies to immune cells without genetic modification, aiming for safer off-the-shelf γδ2 T-cell therapy. This study introduces ACE2016, its EGFR specificity, preclinical efficacy, cytokine and recruitment mechanisms, and in vivo safety signals.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/allogeneic-cetuximab-armed-gamma-delta-t-cells-using-antibody-cell-conjugation-technology-for-the-treatment-of-egfr-expressing-solid-tumors/371665/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/allogeneic-cetuximab-armed-gamma-delta-t-cells-using-antibody-cell-conjugation-technology-for-the-treatment-of-egfr-expressing-solid-tumors/371665.png","ImageObject",300,407,{"name":42,"@type":43},"Đào","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in EGFR-targeted cell therapies?","Question",{"text":63,"@type":64},"It addresses limitations of existing cell therapies, including risks linked to genetic engineering, long waiting times, and high costs of autologous CAR-αβT cell approaches.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is ACE2016 generated and what is its targeting mechanism?",{"text":68,"@type":64},"ACE2016 is produced using antibody-cell conjugation (ACC) technology to conjugate donor-derived γδ2 T cells with the EGFR-specific antibody cetuximab.",{"name":70,"@type":61,"acceptedAnswer":71},"What preclinical results support ACE2016’s therapeutic potential?",{"text":72,"@type":64},"Preclinical data show superior cytotoxicity against EGFR-expressing cancer cell lines, minimal effects on normal cells, enhanced cytotoxic cytokines, recruitment of peripheral cytotoxic cells, and tumor suppression with prolonged survival without in vivo treatment-related toxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371665,1790996978,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Original research  \n Allogeneic cetuximab-armed gamma  \ndelta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors  \nHao-Kang Li  , Tai-Sheng Wu, Ying Ru, Yi-Chiu Kuo, Chia-Yun Lee, Pei-Ju Leng, Yi-Chun Hsieh, Yun-Jung Chiang, Zih-Fei Cheng, Yan-Liang Lin, Shih-Chia Hsiao, Sai-Wen Tang   \nTo cite: Li H-K, Wu T-S, Ru Y, et al. Allogeneic cetuximabarmed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors. Journal for ImmunoTherapy of Cancer 2025;13:e010500 . doi:10.1136/jitc-2024-010500  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-010500](jitc-2024-010500)) .  \nAccepted 16 June 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nAcepodia Biotech Inc, Alameda, California, USA  \nCorrespondence to  \nDr Sai-Wen Tang;  \n[saiwen@acepodiabio.com](saiwen@acepodiabio.com)  \nDr Shih-Chia Hsiao;  \n[sonny@acepodiabio.com](sonny@acepodiabio.com)  \nABSTRACT  \nBackground Targeting epidermal growth factor receptor (EGFR) has become a strategic approach in cancer therapy, using various modalities including chimeric antigen receptor (CAR)-αβT cell therapies. Despite significant advancements in autologous CAR-αβT cell therapies in Bcell lymphoma, current cell therapies face challenges such as potential risks associated with genetic engineering, waiting time and high costs of autologous CAR-αβT cell therapies. Innovations in click chemistry and bioorthogonal chemistry have enabled the development of antibody-cell conjugation (ACC) technology, which links cancer-targeting antibodies to immune cells without genetic modifications, potentially providing a safer profile.  \nMethods In this study, we introduce ACE2016, an innovative allogeneic cell therapy targeting EGFR.  \nACE2016 is generated by ACC technology to conjugate donor-derived γδ2 T cells with the EGFR-specific antibody cetuximab.  \nResults Our preclinical studies demonstrate that ACE2016 exhibits superior cytotoxicity against various EGFR-expressing cancer cell lines and minimal cytotoxic effects on normal cells. Mechanistic studies revealed that ACE2016 enhances cytotoxicity through increased capacity towards EGFR-expressing cancer cells, enhanced levels of cytotoxic cytokines and recruitment of peripheral cytotoxic cells, reflecting significant tumor suppression and prolonged survival in ACE2016-treated groups without causing treatment-related toxicity in vivo.  \nConclusions These findings support the clinical potential of ACE2016 as an off-the-shelf γδ2 T-cell therapy for EGFR-expressing cancers, offering a combination of specificity, scalability, and safety in the development of solid tumor therapy.  \nINTRODUCTION  \nEpidermal growth factor receptor (EGFR) is a receptor tyrosine kinase within the ErbB family, playing a pivotal role in the pathogenesis of various malignancies, including nonsmall cell lung cancer, triple-negative breast  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ The success of autologous chimeric antigen receptor (CAR)-αβT cell therapies in B-cell lymphoma brings a glimmer of hope to patients with cancer; however, current cell therapies still face challenges such as potential risks associated with genetic engineering, long waiting time and high costs of autologous CAR-αβT cell therapies.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ By applying antibody-cell conjugation technology to allogeneic donor-derived γδ2 T cells, a novel offthe-shelf epidermal growth factor receptor (EGFR) -targeted γδ2 T cells, ACE2016, was developed without a need for genetic engineering. This study illustrates the superior efficacy of ACE2016 against solid tumors with various EGFR expression and the activation mechanism of ACE2016 o","cbCairVYteoTjIRP","https://ap.wps.com/l/cbCairVYteoTjIRP","pdf",2729087,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What problem does the study address in EGFR-targeted cell therapies?\",\"answer\":\"It addresses limitations of existing cell therapies, including risks linked to genetic engineering, long waiting times, and high costs of autologous CAR-αβT cell approaches.\"},{\"question\":\"How is ACE2016 generated and what is its targeting mechanism?\",\"answer\":\"ACE2016 is produced using antibody-cell conjugation (ACC) technology to conjugate donor-derived γδ2 T cells with the EGFR-specific antibody cetuximab.\"},{\"question\":\"What preclinical results support ACE2016’s therapeutic potential?\",\"answer\":\"Preclinical data show superior cytotoxicity against EGFR-expressing cancer cell lines, minimal effects on normal cells, enhanced cytotoxic cytokines, recruitment of peripheral cytotoxic cells, and tumor suppression with prolonged survival without in vivo treatment-related toxicity.\"}]","Allogeneic cetuximab-armed gamma delta T cells using antibody-cell conjugation technology for the treatment of EGFR-expressing solid tumors | PDF",1790192567,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d420650d44f7377ed927839237bc83d.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c691bea9776a9b7ccb995f7f8de47a8.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33516de53a36965c268fa293ccebb6ab.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00f17d6e6abb624cba3819b656c7cca7.webp",980,1306]